<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029519</url>
  </required_header>
  <id_info>
    <org_study_id>PRO 2018-03</org_study_id>
    <nct_id>NCT04029519</nct_id>
  </id_info>
  <brief_title>A Multicenter, Open-Label Retreatment Study of the Safety and Effectiveness of PN40082 for Lip Augmentation</brief_title>
  <official_title>A Multicenter, Open-Label Retreatment Study of the Safety and Effectiveness of PN40082 for Lip Augmentation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prollenium Medical Technologies Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Symbio, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Prollenium Medical Technologies Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of retreatment with PN40082 for lip augmentation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open-label clinical study of retreatment of subjects seeking lip
      augmentation who received treatment with either PN40082 or Restylane Silk in prior Protocol
      PRO 2018-02. Subjects meeting the inclusion/exclusion criteria will receive a single
      additional treatment with PN40082
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 21, 2018</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>multicenter, open-label clinical study of retreatment of subjects seeking lip augmentation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Lip Fullness Grading Scale</measure>
    <time_frame>Visit 1/Day 1 to Visit 3/Month 2, 56 Days</time_frame>
    <description>Lip Fullness Grading Scale is a validated 5-point photonumeric rating scale with 0 being very thin lips up to 4 full lips</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Perioral Lines severity scale</measure>
    <time_frame>Visit 1/Day 1 to Visit 3/Month 2, 56 Days</time_frame>
    <description>Change from baseline in this study and change from baseline in the prior controlled study will be summarized for POL, a 4 point rating scale with 0 as a mouth with no perioral lines to 3 a mouth with many deep lines or crevices.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Aesthetic Improvement</measure>
    <time_frame>Visit 1/Day 1 to Visit 3/Month 2, 56 days</time_frame>
    <description>Other efficacy variables include pGAI, a 5 point scale with 1=worse the appearance is worse than the original condition up to 5 very much improved optimal cosmetic result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Aesthetic Improvement</measure>
    <time_frame>Visit 1/Day 1 to Visit 3/Month 2, 56 days</time_frame>
    <description>Other efficacy variables include iGAI, a 5 point scale with 1=worse the appearance is worse than the original condition up to 5 very much improved optimal cosmetic result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swelling Assessment</measure>
    <time_frame>Visit 1/Day 1 to Visit 3/Month 2, 56 days</time_frame>
    <description>Other efficacy variables include Swelling Assessment at Visit 3/Month 2, a 4 point scale with 0 = none up to 4= Severe</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Lip Augmentation</condition>
  <arm_group>
    <arm_group_label>PN40082</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects in this study will receive one open-label treatment with PN40082.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PN40082</intervention_name>
    <description>PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.</description>
    <arm_group_label>PN40082</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In Protocol PRO 2018-02, the subject was in the per-protocol population, i.e., met all
             inclusion/exclusion criteria; received study device, completed Visit 5 within the
             specified window; had LFGS score by the Blinded Evaluating Investigator at Visit
             3/Month 2, and had no significant protocol violations that would affect the treatment
             evaluation.

          2. If female and of childbearing potential, a negative urine pregnancy test at Visit
             1/Day 1 and the subject agrees to use adequate contraception during the study period

          3. Willing to give written informed consent

        Exclusion Criteria:

        1. Women who are pregnant, lactating, or planning a pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacy R. Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Dermatology &amp; Clinical Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Dermatology &amp; Clinical Research Institute</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research, Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schweiger Dermatology, PLLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skintastic</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 18, 2019</study_first_submitted>
  <study_first_submitted_qc>July 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>July 19, 2019</last_update_submitted>
  <last_update_submitted_qc>July 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

